J 2020

2D Germanane Derivative as a Vector for Overcoming Doxorubicin Resistance in Cancer Cells

FOJTŮ, Michaela, Jan BALVAN, Martina RAUDENSKÁ, Tomáš VIČAR, Jiří ŠTURALA et. al.

Základní údaje

Originální název

2D Germanane Derivative as a Vector for Overcoming Doxorubicin Resistance in Cancer Cells

Autoři

FOJTŮ, Michaela (203 Česká republika), Jan BALVAN (203 Česká republika, domácí), Martina RAUDENSKÁ (203 Česká republika, domácí), Tomáš VIČAR (203 Česká republika, domácí), Jiří ŠTURALA (203 Česká republika), Zdeněk SOFER (203 Česká republika), Jan LUXA (203 Česká republika), Jan PLUTNAR (203 Česká republika), Michal MASAŘÍK (203 Česká republika, domácí) a Martin PUMERA (203 Česká republika, garant)

Vydání

Applied Materials Today, Amsterdam, Elsevier, 2020, 2352-9407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

20501 Materials engineering

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 10.041

Kód RIV

RIV/00216224:14110/20:00116361

Organizační jednotka

Lékařská fakulta

UT WoS

000598346500012

Klíčová slova anglicky

2D materials; 4-carboxybutylgermanane; germanane; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 23. 2. 2021 14:42, Mgr. Tereza Miškechová

Anotace

V originále

Cancer resistance to chemotherapeutics is a common problem often encountered in the clinical setting, hampering greatly the conventional therapy of malignant diseases for several decades. No generally efficient mechanism solving this phenomenon was found so far. Cancer cells can adapt to a stress applied in the form of chemotherapeutics and become insensitive to their effects. Under such a selection pressure, the cancer cells acquire features helping them not only to survive the changes in the environment but also to further divide and to form secondary lesions. Therefore, besides developing novel chemotherapeutics, refining the drug delivery mechanisms of the conventional ones is absolutely crucial to defeat the cancer, so we can fully benefit from the effects these therapeutics offer. Here, we demonstrated enhanced delivery of doxorubicin (DOX) to a DOX-resistant ovarian cancer cell line using completely novel 2D material 4-carboxybutylgermanane (Ge-Bu-COOH). In our study, we present Ge-Bu-COOH as a drug carrier evincing high drug-loading efficiency, low cytotoxicity up to the concentration of 2.5 mu g/mL and no hemolysis. Simultaneously, binding DOX to Ge-Bu-COOH increases DOX accumulation in the DOXresistant cell lines. It leads to a significant anticancer efficiency enhancement in A2780/ADR DOX-resistant cell line; with the maximal effect reaching up to 62.8% compared to free DOX. These findings have profound influence on understanding the behaviour of doxorubicin-resistant tumours and open new horizon to manage their treatment. (c) 2020 Elsevier Ltd. All rights reserved.